


## MC-VA-PABC-MMAE

<b>Cat. No.:</b>	HY-147239
<b>CAS No.:</b>	1818864-51-5
<b>Molecular Formula:</b>	C <sub>65</sub> H <sub>99</sub> N <sub>9</sub> O <sub>14</sub>
<b>Molecular Weight:</b>	1230.53
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (81.27 mM; Need ultrasonic)																			
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td><b>1 mM</b></td> <td>0.8127 mL</td> <td>4.0633 mL</td> <td>8.1266 mL</td> </tr> <tr> <td><b>5 mM</b></td> <td>0.1625 mL</td> <td>0.8127 mL</td> <td>1.6253 mL</td> </tr> <tr> <td><b>10 mM</b></td> <td>0.0813 mL</td> <td>0.4063 mL</td> <td>0.8127 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass			1 mg	5 mg	10 mg	<b>1 mM</b>	0.8127 mL	4.0633 mL	8.1266 mL	<b>5 mM</b>	0.1625 mL	0.8127 mL	1.6253 mL	<b>10 mM</b>	0.0813 mL	0.4063 mL	0.8127 mL
Solvent Concentration	Mass																			
	1 mg	5 mg	10 mg																	
<b>1 mM</b>	0.8127 mL	4.0633 mL	8.1266 mL																	
<b>5 mM</b>	0.1625 mL	0.8127 mL	1.6253 mL																	
<b>10 mM</b>	0.0813 mL	0.4063 mL	0.8127 mL																	
	Please refer to the solubility information to select the appropriate solvent.																			
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (2.03 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (2.03 mM); Clear solution</li> </ol>																			

### BIOLOGICAL ACTIVITY

<b>Description</b>	MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor <a href="#">MMAE</a> (HY-15162) <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Auristatin
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Wang Y, et al. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766.

[2]. Cazzamalli S, et al. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. J Control Release. 2017 Jan 28;246:39-45.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA